Balyasny Asset Management »

Inhibikase Therapeutics shares owned by Balyasny Asset Management

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Balyasny Asset Management from 13F filings

Historical chart of Balyasny Asset Management investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Balyasny Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Balyasny Asset Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $30k 18k 1.68
2025-03-31 $178k 81k 2.19

More positions owned by Balyasny Asset Management

State Str Spdr S&p 500 Etf T Tr Unit Call Option (SPY)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Meta Platforms Cl A Call Option (META)
Amazon Call Option (AMZN)
NVIDIA Corporation Call Option (NVDA)
Apple Call Option (AAPL)
Alphabet Cap Stk Cl A Call Option (GOOGL)
Warner Bros Discovery Com Ser A Put Option (WBD)
Raytheon Technologies Corp Call Option (RTX)
Select Sector Spdr Tr State Street Fin Call Option (XLFI)
Select Sector Spdr Tr State Street Ene Call Option (XLE)
Lumentum Hldgs Note 0.500% 6/1 (Principal)
Microsoft Corporation Call Option (MSFT)
Ishares Tr Iboxx Hi Yd Etf Call Option (HYG)

View all positions for Balyasny Asset Management

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Fairmount Funds Management
Trails Edge Capital Partners
ADAR1 Capital Management
BlackRock
Blackstone Group
Siren
Commodore Capital
Vanguard Group
Vanguard Capital Management
Saturn V Capital Management
Kalehua Capital Management
Squadron Capital Management
Millennium Management

View all funds holding Inhibikase Therapeutics